HENLIUS(02696.HK): Completes H-Share Full Circulation, 182.65 Million Unlisted Shares Converted to H-Shares to List Tomorrow
NewTimeSpace News: HENLIUS(02696.HK) issued a notice on February 4, 2026, disclosing that the company’s H-share full circulation has been officially completed. The notice shows that a total of 182.6459 million unlisted shares have been fully converted to H-shares, with the conversion process successfully concluding on February 4, 2026. These converted H-shares will be officially listed on the HKEX and incorporated into the H-share trading system at 9:00 a.m. (Hong Kong Time) on February 5, 2026.
In terms of shareholding structure, HENLIUS’total share capital remains unchanged at 543.4949 million shares before and after the completion of the conversion and listing, with only adjustments to the proportion of different share classes.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HENLIUS(02696.HK): First Patient Dosed in Phase I Clinical Trial of HLX05-N, a Cetuximab Biosimilar, for Metastatic Colorectal Cancer
- HENLIUS(02696.HK): Bispecific EGFR/c-MET ADC HLX48 Doses First Patient
- Henlius (02696.HK) Serplulimab Approved by EU Commission for First-Line sqNSCLC
- Henlius(02696.HK): HLX3902 Injection (STEAP1xCD3xCD28 Trispecific Antibody) Gets NMPA Approval for Phase I Clinical Trial in Metastatic Castration-Resistant Prostate Cancer
- Henlius(02696.HK): Hanbeiyou (Pertuzumab Injection) Passes GMP Compliance Inspection, Songjiang Base Eligible for Commercial Production